# EDGAR Filing Document

**Accession Number:** 0001274225
**File Stem:** 0001104659-25-099782
**Filing Date:** 2025-10
**Character Count:** 8620
**Document Hash:** 929e618305e10030239ee8b26c37813a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-099782.hdr.sgml**: 20251015

**ACCESSION NUMBER**: 0001104659-25-099782

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251014

**FILED AS OF DATE**: 20251015

**DATE AS OF CHANGE**: 20251015

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** LANGER DENNIS
- **CENTRAL INDEX KEY:** 0001274225

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37846
- **FILM NUMBER:** 251395677

**MAIL ADDRESS:**
- **STREET 1:** C/O PETER TSOFLIAS, BLANK ROME LLP
- **STREET 2:** ONE LOGAN SQUARE, FL 9
- **CITY:** PHILADELPHA
- **STATE:** PA
- **ZIP:** 19103
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quoin Pharmaceuticals, Ltd.
- **CENTRAL INDEX KEY:** 0001671502
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 23 HATA'AS STREET
- **CITY:** KFAR SABA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 44425
- **BUSINESS PHONE:** 97299741444

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 23 HATA'AS STREET
- **CITY:** KFAR SABA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 44425

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cellect Biotechnology Ltd.
- **DATE OF NAME CHANGE:** 20160721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cellect Biomed Ltd.
- **DATE OF NAME CHANGE:** 20160406

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>LANGER DENNIS<br><sub>(Last) (First) (Middle)</sub><br>C/O QUOIN PHARMACEUTICALS LTD.,<br>42127 PLEASANT FOREST COURT<br><sub>(Street)</sub><br>ASHBURN, VA 20148<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-14 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Quoin Pharmaceuticals, Ltd. [ QNRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| ADSs<sup>(1)</sup> | 2025-10-14 |  | P<sup>(2)</sup> |  | 15152 | A | $8.49 | 15153 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series H Warrants (Right to Buy) | $9.075 | 2025-10-14 |  | P<sup>(2)</sup> |  | 15152 |  | 2025-10-14<sup>(3)</sup> | <sup>(4)</sup> | ADS<sup>(1)</sup> | 15152 | <sup>(2)</sup> | 15152 | D |  |
| Series I Warrants (Right to Buy) | $10.3125 | 2025-10-14 |  | P<sup>(2)</sup> |  | 15152 |  | 2025-10-14<sup>(3)</sup> | <sup>(5)</sup> | ADS<sup>(1)</sup> | 15152 | <sup>(2)</sup> | 15152 | D |  |
| Series J Warrants (Right to Buy) | $12.375 | 2025-10-14 |  | P<sup>(2)</sup> |  | 15152 |  | 2025-10-14<sup>(3)</sup> | <sup>(6)</sup> | ADS<sup>(1)</sup> | 15152 | <sup>(2)</sup> | 15152 | D |  |
| Series K Warrants (Right to Buy) | $12.375 | 2025-10-14 |  | P<sup>(2)</sup> |  | 15152 |  | 2025-10-14<sup>(3)</sup> | <sup>(7)</sup> | ADS<sup>(1)</sup> | 15152 | <sup>(2)</sup> | 15152 | D |  |

---

### Footnotes:

(1) Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

(2) Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

(3) The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

(4) The Series H Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the Company's public announcement that the Company has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome.

(5) The Series I Warrants will expire as follows: (i) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the monotherapy pivotal trial of QRX003 for the treatment of Netherton Syndrome, and (ii) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the adjuvant pivotal trial of QRX003 for the treatment of Netherton Syndrome.

(6) The Series J Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome.

(7) The Series K Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the Company's sale of a Priority Review Voucher (PRV).

**Signature:** /s/ Dennis Langer  
**Date:** 2025-10-15

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**